advertisement
Journal of Ocular Pharmacology and Therapeutics 20
Showing records 1 to 20 |
Display all abstracts in Journal of Ocular Pharmacology and Therapeutics70528 Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival InjectionLavik E
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 642-649
69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult VolunteersLaties A
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554
70243 Drug-Loaded Nanoparticles Embedded in a Biomembrane Provide a Dual-Release Mechanism for Drug Delivery to the EyeSharma M
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 565-573
70510 Change in Central Corneal Thickness After the Discontinuation of Latanoprost in Normal Tension Glaucoma-Change in Central Corneal Thickness After Stop of LatanoprostYoo R
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 57-61
70115 Ocular Purine Receptors as Drug Targets in the EyeJacobson KA
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 534-547
70243 Drug-Loaded Nanoparticles Embedded in a Biomembrane Provide a Dual-Release Mechanism for Drug Delivery to the EyeBhowmick R
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 565-573
70528 Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival InjectionKuehn MH
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 642-649
69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult VolunteersRich CC
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554
70115 Ocular Purine Receptors as Drug Targets in the EyeCivan MM
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 534-547
70510 Change in Central Corneal Thickness After the Discontinuation of Latanoprost in Normal Tension Glaucoma-Change in Central Corneal Thickness After Stop of LatanoprostChoi YA
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 57-61
69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult VolunteersStoltz R
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554
70510 Change in Central Corneal Thickness After the Discontinuation of Latanoprost in Normal Tension Glaucoma-Change in Central Corneal Thickness After Stop of LatanoprostCho BJ
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 57-61
70528 Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival InjectionShoffstall AJ
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 642-649
70243 Drug-Loaded Nanoparticles Embedded in a Biomembrane Provide a Dual-Release Mechanism for Drug Delivery to the EyeGappa-Fahlenkamp H
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 565-573
70528 Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival InjectionAtkins K
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 642-649
69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult VolunteersHumbert V; Brickman C
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554
70528 Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival InjectionDumitrescu AV
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 642-649
69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult VolunteersMcVicar W
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554
70528 Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival InjectionKwon YH
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 642-649
69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult VolunteersBaumgartner RA
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554
Issue 18-2
Change Issue
advertisement